Sökning: WFRF:(Eisenstat David D.) > (2015) > Molecular subgroups...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06335naa a2201129 4500 | |
001 | oai:DiVA.org:uu-255273 | |
003 | SwePub | |
008 | 150615s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2552732 URI |
024 | 7 | a https://doi.org/10.1016/S1470-2045(15)70114-22 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Torchia, Jonathon4 aut |
245 | 1 0 | a Molecular subgroups of atypical teratoid rhabdoid tumours in children :b an integrated genomic and clinicopathological analysis |
264 | 1 | c 2015 |
338 | a print2 rdacarrier | |
520 | a Background Rhabdoid brain tumours, also called atypical teratoid rhabdoid tumours, are lethal childhood cancers with characteristic genetic alterations of SMARCB1/hSNF5. Lack of biological understanding of the substantial clinical heterogeneity of these tumours restricts therapeutic advances. We integrated genomic and clinicopathological analyses of a cohort of patients with atypical teratoid rhabdoid tumours to find out the molecular basis for clinical heterogeneity in these tumours. Methods We obtained 259 rhabdoid tumours from 37 international institutions and assessed transcriptional profiles in 43 primary tumours and copy number profiles in 38 primary tumours to discover molecular subgroups of atypical teratoid rhabdoid tumours. We used gene and pathway enrichment analyses to discover group-specific molecular markers and did immunohistochemical analyses on 125 primary tumours to evaluate clinicopathological significance of molecular subgroup and ASCL1-NOTCH signalling. Findings Transcriptional analyses identified two atypical teratoid rhabdoid tumour subgroups with differential enrichment of genetic pathways, and distinct clinicopathological and survival features. Expression of ASCL1, a regulator of NOTCH signalling, correlated with supratentorial location (p=0.004) and superior 5-year overall survival (35%, 95% CI 13-57, and 20%, 6-34, for ASCL1-positive and ASCL1-negative tumours, respectively; p=0.033) in 70 patients who received multimodal treatment. ASCL1 expression also correlated with superior 5-year overall survival (34%, 7-61, and 9%, 0-21, for ASCL1-positive and ASCL1-negative tumours, respectively; p=0.001) in 39 patients who received only chemotherapy without radiation. Cox hazard ratios for overall survival in patients with differential ASCL1 enrichment treated with chemotherapy with or without radiation were 2.02 (95% CI 1.04-3.85; p=0.038) and 3.98 (1.71-9.26; p=0.001). Integrated analyses of molecular subgroupings with clinical prognostic factors showed three distinct clinical risk groups of tumours with different therapeutic outcomes. Interpretation An integration of clinical risk factors and tumour molecular groups can be used to identify patients who are likely to have improved long-term radiation-free survival and might help therapeutic stratification of patients with atypical teratoid rhabdoid tumours. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Picard, Daniel4 aut |
700 | 1 | a Lafay-Cousin, Lucie4 aut |
700 | 1 | a Hawkins, Cynthia E.4 aut |
700 | 1 | a Kim, Seung-Ki4 aut |
700 | 1 | a Letourneau, Louis4 aut |
700 | 1 | a Ra, Young-Shin4 aut |
700 | 1 | a Ho, King Ching4 aut |
700 | 1 | a Chan, Tiffany Sin Yu4 aut |
700 | 1 | a Sin-Chan, Patrick4 aut |
700 | 1 | a Dunham, Christopher P.4 aut |
700 | 1 | a Yip, Stephen4 aut |
700 | 1 | a Ng, Ho-Keung4 aut |
700 | 1 | a Lu, Jian-Qiang4 aut |
700 | 1 | a Albrecht, Steffen4 aut |
700 | 1 | a Pimentel, Jose4 aut |
700 | 1 | a Chan, Jennifer A.4 aut |
700 | 1 | a Somers, Gino R.4 aut |
700 | 1 | a Zielenska, Maria4 aut |
700 | 1 | a Faria, Claudia C.4 aut |
700 | 1 | a Roque, Lucia4 aut |
700 | 1 | a Baskin, Berivanu Uppsala universitet,Medicinsk genetik och genomik4 aut0 (Swepub:uu)berba972 |
700 | 1 | a Birks, Diane4 aut |
700 | 1 | a Foreman, Nick4 aut |
700 | 1 | a Strother, Douglas4 aut |
700 | 1 | a Klekner, Almos4 aut |
700 | 1 | a Garami, Miklos4 aut |
700 | 1 | a Hauser, Peter4 aut |
700 | 1 | a Hortobagyi, Tibor4 aut |
700 | 1 | a Bognar, Laszlo4 aut |
700 | 1 | a Wilson, Beverly4 aut |
700 | 1 | a Hukin, Juliette4 aut |
700 | 1 | a Carret, Anne-Sophie4 aut |
700 | 1 | a Van Meter, Timothy E.4 aut |
700 | 1 | a Nakamura, Hideo4 aut |
700 | 1 | a Toledano, Helen4 aut |
700 | 1 | a Fried, Iris4 aut |
700 | 1 | a Fults, Daniel4 aut |
700 | 1 | a Wataya, Takafumi4 aut |
700 | 1 | a Fryer, Chris4 aut |
700 | 1 | a Eisenstat, David D.4 aut |
700 | 1 | a Scheineman, Katrin4 aut |
700 | 1 | a Johnston, Donna4 aut |
700 | 1 | a Michaud, Jean4 aut |
700 | 1 | a Zelcer, Shayna4 aut |
700 | 1 | a Hammond, Robert4 aut |
700 | 1 | a Ramsay, David A.4 aut |
700 | 1 | a Fleming, Adam J.4 aut |
700 | 1 | a Lulla, Rishi R.4 aut |
700 | 1 | a Fangusaro, Jason R.4 aut |
700 | 1 | a Sirachainan, Nongnuch4 aut |
700 | 1 | a Larbcharoensub, Noppadol4 aut |
700 | 1 | a Hongeng, Suradej4 aut |
700 | 1 | a Barakzai, Muhammad Abrar4 aut |
700 | 1 | a Montpetit, Alexandre4 aut |
700 | 1 | a Stephens, Derek4 aut |
700 | 1 | a Grundy, Richard G.4 aut |
700 | 1 | a Schueller, Ulrich4 aut |
700 | 1 | a Nicolaides, Theodore4 aut |
700 | 1 | a Tihan, Tarik4 aut |
700 | 1 | a Phillips, Joanna4 aut |
700 | 1 | a Taylor, Michael D.4 aut |
700 | 1 | a Rutka, James T.4 aut |
700 | 1 | a Dirks, Peter4 aut |
700 | 1 | a Bader, Gary D.4 aut |
700 | 1 | a Warmuth-Metz, Monika4 aut |
700 | 1 | a Rutkowski, Stefan4 aut |
700 | 1 | a Pietsch, Torsten4 aut |
700 | 1 | a Judkins, Alexander R.4 aut |
700 | 1 | a Jabado, Nada4 aut |
700 | 1 | a Bouffet, Eric4 aut |
700 | 1 | a Huang, Annie4 aut |
710 | 2 | a Uppsala universitetb Medicinsk genetik och genomik4 org |
773 | 0 | t The Lancet Oncologyg 16:5, s. 569-582q 16:5<569-582x 1470-2045x 1474-5488 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-255273 |
856 | 4 8 | u https://doi.org/10.1016/S1470-2045(15)70114-2 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy